The Board of Directors of IRLAB has resolved on an 85 per cent secured rights issue of approximately SEK 136 million and receives extended debt financing of SEK 30 million

The Board of Directors of IRLAB Therapeutics AB (“IRLAB” or the “Company”) has today, by virtue of the authorization from the Annual General Meeting on 11 June 2025, resolved on a rights issue of shares of series A of approximately SEK 136 million before deduction of transaction costs (the “Rights Issue”). The subscription price has been determined to SEK 3.50 per share. Those who on the record date 1 July 2025 are registered as shareholders in IRLAB will receive one (1) subscription right for each share held, regardless of share series. Four (4) subscription rights will entitle to subscription for three (3) newly issued shares of series A. The Company has received subscription undertakings from existing shareholders, senior management, and directors, which in total amount to approximately SEK 44 million, corresponding to approximately 33 percent of the Rights Issue. Furthermore, the Company has entered into agreements on guarantee undertakings amounting to a total of approximately SEK 71 million, corresponding to approximately 52 percent of the Rights Issue. Consequently, the Rights Issue is covered by way of subscription undertakings and guarantee undertakings to a total of approximately SEK 116 million, corresponding to approximately 85 percent of the Rights Issue. In addition, the Company announces that the term for SEK 30 million of the existing loan of SEK 55 million from Fenja Capital is extended from 31 December 2025 to 30 October 2026. The remaining SEK 25 million will be repaid either through set-off against shares in the Rights Issue, to the extent its guarantee undertaking for the corresponding amount is utilized, or in cash.